Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 6/20 | 0.47 |
| ▸ | CDK8 | P49336 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KDM6B | O15054 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3539831 | 1.00 | CCNC (0.47) | CCNCCDK8KDM4EALDH1A1MEN1 | |
| SCHEMBL3549167 | 0.86 | CCNC (0.50) | CCNCCDK8KDM4EALDH1A1MEN1 | |
| SCHEMBL3549163 | 0.86 | CCNC (0.50) | CCNCCDK8KDM4EALDH1A1MEN1 | |
| SCHEMBL4072360 | 0.80 | CCNC (0.51) | CCNCCDK8KDM4EALDH1A1MEN1 | |
| SCHEMBL16795885 | 0.79 | MAPT (0.48) | CCNCCDK8KDM4EALDH1A1MAPT | |
| SCHEMBL9757050 | 0.79 | CCNC (0.54) | CCNCCDK8KDM4EALDH1A1CA1 | |
| SCHEMBL9757045 | 0.79 | CCNC (0.54) | CCNCCDK8KDM4EALDH1A1CA1 | |
| SCHEMBL18169371 | 0.79 | MAPT (0.48) | CCNCCDK8KDM4EALDH1A1MAPT | |
| SCHEMBL23540351 | 0.78 | PAM (0.43) | CCNCCDK8KDM4EALDH1A1MEN1 | |
| SCHEMBL17346861 | 0.77 | CCNC (0.54) | CCNCCDK8CA1CA2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577219-B2 | Macrolide brefeldin a ester derivatives and use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2026-03-17 | — | — | US | disclosed |
| US-20220064138-A1 | MACROLIDE BREFELDIN A ESTER DERIVATIVES AND USE THEREOF | OCEAN UNIVERSITY OF CHINA (CN) | 2022-03-03 | — | — | US | disclosed |
| EP-3154970-B1 | PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILARY TANGLES | MERCK SHARP & DOHME (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10022461-B2 | Pyrrolo[2,3-C]pyridines as imaging agents for neurofibrilary tangles | MERCK SHARP & DOHME CORP. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180071412-A1 | PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILARY TANGLES | MERCK SHARP & DOHME CORP. (US) | 2018-03-15 | — | — | US | disclosed |
| US-9808542-B2 | Pyrrolo[2,3-C]pyridines as imaging agents for neurofibrillary | MERCK SHARP & DOHME CORP. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170119912-A1 | PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILLARY | MERCK SHARP & DOHME CORP. (US) | 2017-05-04 | — | — | US | disclosed |
| EP-3154970-A2 | PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILARY TANGLES | Merck Sharp & Dohme Corp. (US) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015188368-A1 | PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILARY TANGLES | MERCK SHARP & DOHME CORP. (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015191506-A2 | PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILARY TANGLES | MERCK SHARP & DOHME CORP. (US) | 2015-12-17 | — | — | WO | disclosed |
| US-8198282-B2 | Substituted azaquinazolines having an antiviral action | AICURIS GMBH & CO. KG (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20100179174-A1 | SUBSTITUTED AZAQUINAZOLINES HAVING AN ANTIVIRAL ACTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-15 | — | — | US | disclosed |
| US-7662822-B2 | Substituted azaquinazolines having an antiviral action | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-16 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20080132515-A1 | antiviral agents, in particular against cytomegaloviruses; {2-[4-(4-Fluorophenyl)piperazin-1-yl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrido[3,4-d]-pyrimidin-4-yl}acetic acid hydrochloride | BAYER HEALTHCARE AG (DE) | 2008-06-05 | — | — | US | disclosed |
| CN-1980925-A | Substituted azaquinazolines with antiviral activity | AICURIS GMBH & CO KG (DE) | 2007-06-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064138-A1 | MACROLIDE BREFELDIN A ESTER DERIVATIVES AND USE THEREOF | MAN2B1, MAN1B1, FUCA1 | CCNC 2563/4885CDK8 3468/4885KDM4E 4154/4885 |
| US-10022461-B2 | Pyrrolo[2,3-C]pyridines as imaging agents for neurofibrilary tangles | MAPT, SNCA, PARK7 | CCNC 2221/4885CDK8 4551/4885KDM4E 3496/4885 |
| US-12577219-B2 | Macrolide brefeldin a ester derivatives and use thereof | BCL6, BCL6B, BCL3 | CCNC 1396/4885CDK8 3059/4885KDM4E 4222/4885 |
| US-20080132515-A1 | antiviral agents, in particular against cytomegaloviruses; {2-[4-(4-Fluorophenyl)piperazin-1-yl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrido[3,4-d]-pyrimidin-4-yl}acetic acid hydrochloride | ZC3HAV1, EIF2AK2, IRF3 | CCNC 190/4885CDK8 155/4885KDM4E 1009/4885 |
| US-20170119912-A1 | PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILLARY | MAPT, SNCA, PARK7 | CCNC 1700/4885CDK8 4528/4885KDM4E 3658/4885 |
| US-20180071412-A1 | PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILARY TANGLES | MAPT, SNCA, PARK7 | CCNC 2221/4885CDK8 4551/4885KDM4E 3496/4885 |
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | CCNC 644/4885CDK8 126/4885KDM4E 4055/4885 |
| US-20100179174-A1 | SUBSTITUTED AZAQUINAZOLINES HAVING AN ANTIVIRAL ACTION | EIF2AK2, TPMT, IRF3 | CCNC 348/4885CDK8 32/4885KDM4E 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.